Gambro launches the next generation of 
high-flux dialyzers with Polyflux Revaclear and Polyflux Revaclear MAX
DENVER, Colo. — Gambro, a leader in advancing dialyzer technology for more than 40 years, announced today that it is introducing the latest innovation in dialyzer technology — Polyflux® Revaclear and Polyflux® Revaclear MAX. The Polyflux Revaclear dialyzers feature a proprietary membrane technology and an advanced design, which combine to deliver outstanding clinical performance for treatment of dialysis patients. Polyflux Revaclear and Polyflux Revaclear MAX will be broadly available in United States and Canada during first quarter of 2009.
“The new Polyflux Revaclear dialyzers exemplify Gambro’s commitment to delivering innovative products that provide value and dialysis delivery for providers and patients,” said Juan Bosch, M.D., Chief Medical Officer for Gambro. “Polyflux Revaclear combines the proven performance of the Polyflux dialyzer with an advanced design that delivers outstanding clinical results in an economically and environmentally sensible package.”
New Membrane and Innovative Design
The Polyflux Revaclear and Polyflux Revaclear MAX high-flux dialyzers feature a new membrane that is more efficient and more selective while retaining the same proven 3-layer membrane structure as the existing Polyflux dialyzer. The membrane is composed of a unique blend of the polymers PAES (Polyarylethersulfone) and PVP (Polyvinylpyrrolidone).
Studies have demonstrated that the Revaclear dialyzers’ advanced design offers enhanced performance with a smaller, smoother membrane surface, with the potential to improve patient outcomes and efficiencies for providers:
• A smoother membrane surface area results in reduced thrombogenic potential
• Improved hollow fiber geometry, with thinner fibers, allows Revaclear MAX to achieve the same degree of solute clearance as the original Polyflux, despite a significant reduction in membrane surface area.
• A β2-microglobulin clearance that results in significant potential for lowering β2-microglobulin levels which may help to reduce morbidity and mortality in patients.
• Improved device design provides a uniform flow distribution in both the blood and dialysate compartments, contributing to enhanced solute clearance and low thrombogenicity.
The design and performance ensure that all adult patients can be treated using only two sizes of dialyzers — (Polyflux Revaclear (1.4m2) and Polyflux Revaclear MAX (1.8m2).
The Revaclear dialyzers’ advanced and efficient design is also more economical and a reduced environmental impact than the original Polyflux. The Revaclear dialyzers are smaller and therefore require less material and energy consumption in manufacturing. Their compact design also can help reduce transportation, storage and biohazardous waste-disposal costs.
For more information about the Polyflux Revaclear products and other Gambro solutions for delivering in-center hemodialysis please contact:
Anne Bonelli, Director of Marketing Communications, Americas Tel: +1 (303) 231-4671
1Cheung AK, Rocco MV, Yan G et al. Serum beta-2microglobulin levels predict mortality in dialysis patients: results of the HEMO study. J Am Soc Nephrol. 2006 Feb;17(2):546-555.
2 Gao, D. Data on file, Gambro Inc., Lakewood, CO, USA.